PER - Megathread, page-216

Percheron presents at Cantor Muscular Dystrophy Symposium Dear Shareholder, Percheron CEO, Dr James Garner, was recently invited to speak at the Cantor Virtual Muscular Dystrophy Symposium. The symposium was organised by Cantor Fitzgerald LP, an international investment bank based in New York, NY. In a wide-ranging ‘fireside chat’ with Dr Rick Miller, Vice President of Biotech Equity Research at Cantor, Dr Garner described some of the key features of ATL1102, and how it may be situated within the treatment landscape for Duchenne muscular dystrophy. We are pleased to be able to share the interview for your interest via the following link: https://wsw.com/webcast/cantor20/per.xa/2339486 The conference agenda also included discussions with a number of other companies working in the muscular dystrophy field, including Edgewise Therapeutics, Capricor Therapeutics, Wave Live Sciences, and Sarepta Therapeutics. In addition, the agenda featured several panel discussions with clinician key opinion leaders. Attendees to the conference comprised a diverse range of US-based life science investors, pharmaceutical companies, and patient advocacy organisations. We look forward to continuing to keep you informed of our progress. Yours, Percheron Therapeutics Investor Relations [email protected]